BioSelective Capital Investments and Shayan Enterprises, LLC, a Utah-based risk-capital investment firm,  announced the successful acquisition of BioDuro’s drug product development and manufacturing operations in Irvine, California, resulting in the formation of Forma Life Sciences, Inc. (FORMA), a Delaware corporation established to hold and operate the acquired assets.

The transaction includes two highly accredited facilities supporting U.S.-based development and manufacturing of high-quality pharmaceutical drug products. Now operating under the FORMA name, the Irvine Fairbanks facility comprises approximately 65,000 sq. ft. and has produced high-value pharmaceutical drug products for more than 20 years, with a strong regulatory track record including multiple FDA inspections with favorable outcomes. In parallel, the Irvine Jeronimo facility encompasses approximately 40,000 sq. ft. and is focused on development and scale-up manufacturing of clinical-phase drug products, with purpose-built manufacturing suites designed to enable advanced oral solid dosage technologies.

“This acquisition represents a meaningful expansion of our capabilities and reinforces our long-standing commitment to U.S.-based development, manufacturing, and supply of critical drug products for both domestic and global partners,” said Cyrus K. Mirsaidi, Chairman of BioSelective Capital Investments. “We sincerely appreciate the collaborative engagement with BioDuro and its investors throughout this transaction and look forward to continuing the relationship as a trusted U.S. manufacturing partner for oral dosage forms.”

Following the acquisition, Cyrus K. Mirsaidi will serve as Executive Chairman and Acting Chief Executive Officer of FORMA. The company is focused on ensuring continuity for existing clients while laying the foundation for the next phase of growth in its core commercial drug product manufacturing business. FORMA also plans to expand into differentiated capabilities in bioavailability enhancement, including advancements in amorphous solid dispersion technologies and rapid formulation prototyping enabled by iterative in silico modeling.